Literature DB >> 19373466

Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment.

Hirofumi Taki1, Yukio Kawagishi, Koichiro Shinoda, Hiroyuki Hounoki, Reina Ogawa, Eiji Sugiyama, Kazuyuki Tobe.   

Abstract

Tumor necrosis factor (TNF)-α inhibitors are increasingly being used to treat rheumatoid arthritis. Infliximab (INF) is a TNF-α inhibitor that is usually used in combination with methotrexate (MTX). Interstitial lung disease (ILD) during combination therapy has been attributed to MTX rather than INF. However, INF-associated ILD without combination with MTX has recently been reported. We describe herein a case of severe ILD secondary to INF without MTX therapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19373466     DOI： 10.1007/s00296-009-0931-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  10 in total

1.  Interstitial pneumonitis associated with infliximab therapy.

Authors:  Edith Villeneuve; Anne St-Pierre; Boulos Haraoui
Journal:  J Rheumatol       Date:  2006-04-15       Impact factor: 4.666

2.  Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis.

Authors:  Neil Kramer; Yelena Chuzhin; Lee D Kaufman; Jill M Ritter; Elliot D Rosenstein
Journal:  Arthritis Rheum       Date:  2002-12-15

3.  Severe interstitial pneumonitis associated with infliximab therapy.

Authors:  S Chatterjee
Journal:  Scand J Rheumatol       Date:  2004       Impact factor: 3.641

4.  Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis.

Authors:  E Bargagli; M Galeazzi; P Rottoli
Journal:  Eur Respir J       Date:  2004-10       Impact factor: 16.671

5.  Interstitial pneumonitis after infliximab therapy for Crohn's disease.

Authors:  Mark Weatherhead; Steven Masson; Stephen J Bourke; Melanie C Gunn; Graham P Burns
Journal:  Inflamm Bowel Dis       Date:  2006-05       Impact factor: 5.325

6.  Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody.

Authors:  Shunsuke Mori; Fumiya Imamura; Chikage Kiyofuji; Mineharu Sugimoto
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

7.  Azathioprine-associated interstitial pneumonitis.

Authors:  C W Bedrossian; J Sussman; R H Conklin; B Kahan
Journal:  Am J Clin Pathol       Date:  1984-08       Impact factor: 2.493

8.  Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition.

Authors:  Robert Vassallo; Eric Matteson; Charles F Thomas
Journal:  Chest       Date:  2002-09       Impact factor: 9.410

9.  Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.

Authors:  Andrew J K Ostör; Edwin R Chilvers; Margaret F Somerville; Anita Y N Lim; Suzanne E Lane; Adrian J Crisp; David G I Scott
Journal:  J Rheumatol       Date:  2006-03       Impact factor: 4.666

10.  Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis.

Authors:  Kiyofumi Hagiwara; Takeo Sato; Shoko Takagi-Kobayashi; Shunsuke Hasegawa; Nayumi Shigihara; Osamu Akiyama
Journal:  J Rheumatol       Date:  2007-04-15       Impact factor: 4.666
  10 in total
  7 in total

Review 1.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

Review 2.  Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced.

Authors:  Robert W Hallowell; Maureen R Horton
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 3.  Noninfectious interstitial lung disease during infliximab therapy: case report and literature review.

Authors:  Roberta Caccaro; Edoardo Savarino; Renata D'Incà; Giacomo Carlo Sturniolo
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

4.  Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors.

Authors:  Dario R Lemos; Farshad Babaeijandaghi; Marcela Low; Chih-Kai Chang; Sunny T Lee; Daniela Fiore; Regan-Heng Zhang; Anuradha Natarajan; Sergei A Nedospasov; Fabio M V Rossi
Journal:  Nat Med       Date:  2015-06-08       Impact factor: 53.440

5.  2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Authors:  Liana Fraenkel; Joan M Bathon; Bryant R England; E William St Clair; Thurayya Arayssi; Kristine Carandang; Kevin D Deane; Mark Genovese; Kent Kwas Huston; Gail Kerr; Joel Kremer; Mary C Nakamura; Linda A Russell; Jasvinder A Singh; Benjamin J Smith; Jeffrey A Sparks; Shilpa Venkatachalam; Michael E Weinblatt; Mounir Al-Gibbawi; Joshua F Baker; Kamil E Barbour; Jennifer L Barton; Laura Cappelli; Fatimah Chamseddine; Michael George; Sindhu R Johnson; Lara Kahale; Basil S Karam; Assem M Khamis; Iris Navarro-Millán; Reza Mirza; Pascale Schwab; Namrata Singh; Marat Turgunbaev; Amy S Turner; Sally Yaacoub; Elie A Akl
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-06-08       Impact factor: 5.178

Review 6.  Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis.

Authors:  Kuang-Hui Yu; Hsin-Hua Chen; Tien-Tsai Cheng; Yeong-Jian Jan; Meng-Yu Weng; Yeong-Jang Lin; Hung-An Chen; Jui-Tseng Cheng; Kuang-Yung Huang; Ko-Jen Li; Yu-Jih Su; Pui-Ying Leong; Wen-Chan Tsai; Joung-Liang Lan; Der-Yuan Chen
Journal:  Medicine (Baltimore)       Date:  2022-01-07       Impact factor: 1.889

Review 7.  Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis.

Authors:  Shunsuke Mori
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-09-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.